C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a non-interventional treatment Registry of Hereditary Angioedema (HAE) patients treated with C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (rhC1INH / Ruconest), to observe adverse events and insufficient efficacy, and to assess the immunological profile following single and repeated treatment with Ruconest.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pharming Technologies B.V.
• Treatments: Complement C1 Inactivator Proteins; Complement C1 Inhibitor Protein

Criteria

Inclusion Criteria:

• Decision to treat the HAE patient with C1 inhibitor (either Ruconest or pdC1INH)

• Patients must give written informed consent

Exclusion Criteria:

• A diagnosis of acquired C1INH deficiency (AAE)